Banque Cantonale Vaudoise Acquires 43,970 Shares of Avantor, Inc. (NYSE:AVTR)

Banque Cantonale Vaudoise grew its stake in Avantor, Inc. (NYSE:AVTR) by 66.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 109,777 shares of the company’s stock after purchasing an additional 43,970 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Avantor were worth $2,840,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in AVTR. Swedbank AB bought a new position in shares of Avantor during the first quarter worth $2,707,000. Sound Shore Management Inc. CT acquired a new position in Avantor in the second quarter valued at about $76,412,000. Seven Eight Capital LP bought a new stake in shares of Avantor in the second quarter worth about $642,000. New York State Teachers Retirement System acquired a new stake in shares of Avantor during the third quarter worth about $8,473,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Avantor by 35.1% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,157,855 shares of the company’s stock valued at $24,547,000 after purchasing an additional 300,579 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Avantor Stock Performance

Shares of AVTR stock opened at $19.72 on Wednesday. The company has a fifty day moving average price of $24.27 and a two-hundred day moving average price of $23.94. Avantor, Inc. has a one year low of $19.23 and a one year high of $28.00. The stock has a market cap of $13.42 billion, a P/E ratio of 42.86, a P/E/G ratio of 2.52 and a beta of 1.35. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06.

Insider Activity

In other news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the transaction, the chief accounting officer now directly owns 29,544 shares in the company, valued at approximately $740,372.64. The trade was a 10.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on AVTR shares. Wells Fargo & Company lowered their target price on Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Stifel Nicolaus raised their price objective on shares of Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, July 29th. UBS Group reduced their target price on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, October 8th. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price target on shares of Avantor in a research note on Thursday, September 26th. Finally, Morgan Stanley upped their price objective on Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a research report on Monday, July 29th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, Avantor has an average rating of “Moderate Buy” and a consensus price target of $27.57.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.